Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (81-90 of 174) with videos related to

Pageof 18
Sort By:
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
The American Journal of Surgical Pathology|September 5, 2020
Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic DifferentiationPier Selenica, Niamh Conlon, Carlene Gonzalez, et al.
The American Journal of Surgical Pathology|March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of FibrosarcomaSarah Chiang, Paolo Cotzia, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 29, 2015
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the OvaryJennifer J Mueller, Marie Holzapfel, Chan H Han, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
British Journal of Cancer|May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trialsTomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Pageof 18

Showing results (81-90 of 174) with videos related to

Sort By:
Pageof 18
JCO Precision Oncology|September 11, 2020
Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With <i>BRAF</i> V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET StudyVivek Subbiah, Radj Gervais, Gregory Riely, et al.
Blood|May 23, 2014
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester diseaseEli L Diamond, Lorenzo Dagna, David M Hyman, et al.
The American Journal of Surgical Pathology|September 5, 2020
Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic DifferentiationPier Selenica, Niamh Conlon, Carlene Gonzalez, et al.
The American Journal of Surgical Pathology|March 20, 2018
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of FibrosarcomaSarah Chiang, Paolo Cotzia, David M Hyman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2019
High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation BurdenRyma Benayed, Michael Offin, Kerry Mullaney, et al.
Cancer Research|January 16, 2019
Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase FusionsEmiliano Cocco, Jamal Benhamida, Sumit Middha, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 29, 2015
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the OvaryJennifer J Mueller, Marie Holzapfel, Chan H Han, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
British Journal of Cancer|May 26, 2018
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trialsTomoya Yokota, Johanna Bendell, Patricia LoRusso, et al.
Cancer|December 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathwayMaria M Rubinstein, David M Hyman, Imogen Caird, et al.
Pageof 18